ArticleQuantitative imaging in medicine and surgery2022
Quantitative assessment of intratumoral 2-[
Article in Quantitative imaging in medicine and surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- 18F-FDG PET/CT Findings to Improve Confidence in Distinguishing Lung External Beam Radiotherapy Side Effects.Life (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The purpose of this study was to evaluate the value of quantitative assessment of intratumoral 2-deoxy-2-[ Methods: In this retrospective study, a total of 564 patients with pulmonary lesions who underwent 2-[ Results: The malignant tumors presented significantly higher Q-FMSD values than the benign lesions (1.11 Conclusions: Q-FMSD provides a simply and quantitative indicator for differentiating hypermetabolic pulmonary lesions with higher diagnostic performance than conventional PET/CT methods. Therefore, Q-FMSD should be recommended as a new promising marker to improve the diagnostic performance of hypermetabolic pulmonary lesions in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.